These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16044018)

  • 1. A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV.
    van Oosterhout JJ; Laufer MK; Graham SM; Thumba F; Perez MA; Chimbiya N; Wilson L; Chagomerana M; Molyneux ME; Zijlstra EE; Taylor TE; Plowe CV
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):626-31. PubMed ID: 16044018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
    Laurens MB; Mungwira RG; Nyirenda OM; Divala TH; Kanjala M; Muwalo F; Mkandawire FA; Tsirizani L; Nyangulu W; Mwinjiwa E; Taylor TE; Mallewa J; Blackwelder WC; Plowe CV; Laufer MK; van Oosterhout JJ
    Trials; 2016 Jul; 17(1):322. PubMed ID: 27431995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
    Murri R; Ammassari A; Pezzotti P; Cingolani A; De Luca A; Pallavicini F; Grillo R; Antinori A
    J Acquir Immune Defic Syndr; 2001 May; 27(1):49-55. PubMed ID: 11404520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Tocchetti A; Tambini R; Allegro A; Longoni E; Rinaldi E
    AIDS; 1994 Feb; 8(2):272-4. PubMed ID: 8043236
    [No Abstract]   [Full Text] [Related]  

  • 5. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Bucher HC; Griffith L; Guyatt GH; Opravil M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis carinii pneumonia with concurrent leucovorin use.
    Razavi B; Lund B; Allen BL; Schlesinger L
    Infection; 2002 Jan; 30(1):41-2. PubMed ID: 11876516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis.
    Yazdanpanah Y; Losina E; Anglaret X; Goldie SJ; Walensky RP; Weinstein MC; Toure S; Smith HE; Kaplan JE; Freedberg KA;
    AIDS; 2005 Aug; 19(12):1299-308. PubMed ID: 16052085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and secondary prophylaxis for Pneumocystis carinii related complications in HIV patients.
    Held M; Goebel FD
    Eur Respir J; 1996 May; 9(5):868-71. PubMed ID: 8793444
    [No Abstract]   [Full Text] [Related]  

  • 9. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
    Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
    Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should cotrimoxazole prophylaxis be taken by all adults with HIV in Africa?
    Mermin J; Lule JR; Ekwaru JP; Pitter C
    AIDS; 2005 May; 19(8):845-6. PubMed ID: 15867506
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylaxis of pneumocystis pneumonia and toxoplasmosis.
    Zamora L; Mallolas J; Gatell JM
    Ann Intern Med; 1996 Jun; 124(12):1096. PubMed ID: 8633828
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
    Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
    Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
    Bossi P; Caumes E; Astagneau P; Li TS; Paris L; Mengual X; Katlama C; Bricaire F
    Rev Med Interne; 1998 May; 19(5):313-7. PubMed ID: 9775164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Grünewald T; Behnsch M; Grobusch M; Vallée M; Wünsche T; Ruf B; Suttorp N
    J Infect; 2001 Jan; 42(1):8-15. PubMed ID: 11243747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
    Payen MC; De Wit S; Sommereijns B; Clumeck N
    Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group.
    Anglaret X; Chêne G; Attia A; Toure S; Lafont S; Combe P; Manlan K; N'Dri-Yoman T; Salamon R
    Lancet; 1999 May; 353(9163):1463-8. PubMed ID: 10232311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
    Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
    Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of the prevention of cerebral toxoplasmosis].
    Katlama C
    J Neuroradiol; 1995 Sep; 22(3):193-5. PubMed ID: 7472536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe bacterial infections after prophylactic suppression of Pneumocystis carinii in HIV infected patients after CD4 lymphocyte recovery].
    Boix V; Murcia JM; Merino E; Portilla J
    Med Clin (Barc); 2002 Jun; 118(20):796-7. PubMed ID: 12049699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.